Mutation of TP53, a major player in DNA damage response, is one of the few genetic lesions present in 5–7% of all CLL cases [64], and also aggressive B cell lymphoma [65] TP53 activates the intrinsic apoptotic pathway by inducing several BH3- only proteins [66], while TP53 disruption is recognized as a strong predictor of chemoimmunotherapy resistance in patients with B cell lymphoma [67]. Here, TP53 is linked to B-cell non-Hodgkin lymphoma.